Terapia de procesamiento cognitivo asistida por psilocibina para el trastorno de estrés postraumático crónico
Terapia de procesamiento cognitivo masivo asistida por psilocibina para el trastorno de estrés postraumático crónico: un ensayo abierto
This is an open-label trial evaluating feasibility, tolerability, safety and efficacy of psilocybin assisted cognitive processing therapy for chronic Posttraumatic Stress Disorder (PTSD).
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Descripción detallada
Current front-line treatments for Posttraumatic stress disorder (PTSD) are ineffective for up to half of patients, with serious medical and societal consequences. It is imperative to improve the efficacy of front-line treatment options, such as cognitive processing therapy (CPT). CPT is an effective treatment for PTSD, including when delivered intensively (i.e., multiple sessions over 7 days). However, a substantial proportion of patients continue to meet criteria for PTSD or have residual PTSD symptoms post-treatment. Psilocybin-assisted CPT may be a potential solution, as preliminary evidence supports the potential of psilocybin to alleviate symptoms of PTSD.
Fifteen participants will receive a single dose of psilocybin 25mg combined with 12 sessions of massed CPT, and 2 psychotherapy sessions related to psilocybin over 7 days. Participants will complete clinician-administered scales, self-reported mental health questionnaires, and use a wearable device. After the 1-week interventional period, participants will enter a 12-weeks follow-up period.
Tipo de estudio
Tipo de estudio
Inscripción (Estimado)
Inscripción
Fase
Fase
- Fase 2
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Ontario
-
Toronto, Ontario, Canadá, M5S 1A1
- St. Michael's Hospital, Unity Health Toronto
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Meet Diagnostic and Statistical Manual-5th edition (DSM-5) criteria for current PTSD with a duration of 6 months or longer assessed by study psychiatrist;
- Have a Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) score of 50 or higher, indicating moderate to severe PTSD symptoms;
- Are willing to refrain from taking any psychiatric medications during the study period.
Exclusion Criteria:
- Are pregnant or nursing, or are women of child bearing potential who are not practicing an effective means of birth control;
- Have a history of or a current primary diagnosis of psychotic disorder, schizophrenia, delusional disorder, borderline personality disorder, schizoaffective disorder, bipolar disorder or, dissociative identity disorder;
- Have evidence or history of coronary artery disease or cerebral or peripheral vascular disease, hepatic disease with abnormal liver enzymes, or any other medical disorder judged by the investigator to significantly increase the risk of psilocybin administration;
- Have hypertension using the standard criteria of the American Heart Association (values of 140/90 or higher assessed on three separate occasions;
- History of seizure disorder;
- Uncontrolled insulin-dependent diabetes;
- Recent stroke, intracranial or subarachnoid hemorrhage (< 1 year from signing of informed consent form [ICF]), recent myocardial infarction (< 1 year from signing of ICF), clinically significant arrhythmia (< 1 year from signing of ICF);
- Have liver disease with the exception of asymptomatic subjects with Hepatitis C who have previously undergone evaluation and successful treatment;
- Lifetime history of substance-induced psychosis;
- Lifetime history of substance use disorder with a hallucinogen;
- History of alcohol use disorder in the past 3 months.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Experimental: Experimental
Single dose of psilocybin 25mg + Massed cognitive processing therapy |
Participants will receive a single dose of psilocybin 25mg combined with 12 sessions of massed CPT, and 2 psychotherapy sessions related to psilocybin over 7 days. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Feasibility and tolerability
Periodo de tiempo: Up to 16 weeks
|
Recruitment rate, withdrawal rate, adherence rate, data completion rate, percentage of participants with severe adverse events. |
Up to 16 weeks
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Cuestionario de Trauma Infantil-forma corta (CTQ-SF)
Periodo de tiempo: Cribado
|
Cribado
|
|
|
Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) total score
Periodo de tiempo: Up to 16 weeks
|
The CAPS-5 is a semi-structured clinical interview used to assess index history of DSM-5-defined traumatic event exposure, including the most distressing event, time since exposure, and total number of exposures, as well as frequency and severity of posttraumatic stress symptoms. |
Up to 16 weeks
|
|
Posttraumatic stress disorder Checklist-5 (PCL-5)
Periodo de tiempo: Up to 16 weeks
|
The PCL-5 is self-report questionnaire in which respondents indicate the presence and severity of PTSD symptoms, derived from the DSM-5 symptoms of PTSD. |
Up to 16 weeks
|
|
Patient Health Questionnaire-9 (PHQ-9)
Periodo de tiempo: Up to 16 weeks
|
The PHQ-9 is a self-rated measure of depressive symptom severity in the past two weeks. Each of the nine items is rated on a Likert scale, ranging from 0 (not at all) to 3 (nearly every day), and summed for a total score between 0 (no symptoms) to 27 (most severe). |
Up to 16 weeks
|
|
Generalized Anxiety Disorder Scale, 7-item (GAD-7)
Periodo de tiempo: Up to 16 weeks
|
Total score ranges from 0 to 21; a higher score denotes greater symptom severity. |
Up to 16 weeks
|
|
Dissociative Experiences Scale II (DES-II)
Periodo de tiempo: Up to 13 weeks
|
The Dissociative Experiences Scale II is a 28-item, self-report measure of dissociative experiences. |
Up to 13 weeks
|
|
Pittsburgh Sleep Quality Index (PSQI)
Periodo de tiempo: Up to 13 weeks
|
The PSQI is a self-rated questionnaire which assesses sleep quality and disturbances over a 1-month time interval. |
Up to 13 weeks
|
|
World Health Organization Well-Being Index, 5-item (WHO-5)
Periodo de tiempo: Up to 16 weeks
|
The WHO-5 is a measure of overall well-being, rated on a scale of 0 to 25, with higher scores denoting higher quality of life. |
Up to 16 weeks
|
|
Quality of relationships inventory (QRI)
Periodo de tiempo: Up to 13 weeks
|
The QRI is a self-report questionnaire used to determine the quality relationships consisting of 25 items that are evaluated on a 4-point Likert scale ranging from 1 = not true to 4 = almost always true. |
Up to 13 weeks
|
|
Inventory of psychosocial functioning (IPF)
Periodo de tiempo: Up to 13 weeks
|
The IPF is an 80-item self-report instrument measuring PTSD-related functional impairment in the past 30 days. |
Up to 13 weeks
|
|
Posttraumatic Maladaptive Beliefs Scale (PMBS)
Periodo de tiempo: Up to 13 weeks
|
The PMBS is a 15-item scale that was developed to measure maladaptive beliefs about life circumstances that may occur following trauma exposure. |
Up to 13 weeks
|
|
Brief Experiential Avoidance Questionnaire (BEAQ)
Periodo de tiempo: Up to 13 weeks
|
The BEAQ is a 15-item self-report measure of experiential avoidance. |
Up to 13 weeks
|
|
24-items Multidimensional Psychological Flexibility Inventory (MPFI-24)
Periodo de tiempo: Up to 13 weeks
|
The MPFI-24 is a 24-item self-report scale developed to assess the specific components of psychological flexibility and inflexibility. |
Up to 13 weeks
|
|
Working Alliance Inventory- Short Form (WAI-SF)
Periodo de tiempo: Up to Day 7
|
The WAI-SF is a patient-rated measure of the alliance between a therapist and client. |
Up to Day 7
|
|
Difficulties in Emotion Regulation Scale-Short Form (DERS-SF)
Periodo de tiempo: Up to 13 weeks
|
The DERS-SF is an 18-item measure used to identify emotional regulation issues in adults. |
Up to 13 weeks
|
|
Self-Compassion Scale-Short Form (SCS-SF)
Periodo de tiempo: Up to 13 weeks
|
The SCS-SF is a 12-item self-report measure of self-compassion. |
Up to 13 weeks
|
|
Psychological Insight Questionnaire (PIQ)
Periodo de tiempo: Up to Day 3
|
The PIQ is a 23-item self-report measure of acute experiences of insight (e.g. awareness into emotions, behaviors, beliefs, memories, or relationships) after taking a psychedelic. |
Up to Day 3
|
|
Emotional Breakthrough Inventory (EBI)
Periodo de tiempo: Up to Day 3
|
The EBI is a measure of emotional release/breakthrough experienced during the acute psychedelic state. |
Up to Day 3
|
|
Altered States of Consciousness Rating Scale (ASC)
Periodo de tiempo: Up to Day 3
|
The ASC measures altered states of consciousness. |
Up to Day 3
|
|
Acceptance/Avoidance-Promoting Experiences Questionnaire (APEQ)
Periodo de tiempo: Up to Day 3
|
The APEQ is a psychometric self-report tool for measuring aspects of the acute psychedelic experience that are associated with longer-term changes in psychological flexibility. |
Up to Day 3
|
Otras medidas de resultado
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Effect on digital physiological passive data collected through the use of a wearable device
Periodo de tiempo: Up to 16 weeks
|
Example: sleep, activity |
Up to 16 weeks
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Colaboradores
Colaboradores
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Inicio del estudio
Finalización primaria (Estimado)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Trastornos relacionados con el trauma y el estrés
- Desordenes mentales
- Trastornos de Estrés, Traumáticos
- Trastornos de estrés postraumático
- Compuestos heterocíclicos
- Compuestos heterocíclicos, 2 anillos
- Compuestos heterocíclicos, anillo fusionado
- Alcaloides
- Indoles
- Alcaloides de indol
- Indolizidinas
- Indolizinas
- Triptaminas
- Psilocibina
Otros números de identificación del estudio
Otros números de identificación del estudio
- 23-230
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .